Targeting neuraminidase: the next frontier for broadly protective influenza vaccines.
antibody
immunogen design
influenza virus
neuraminidase
vaccine
Journal
Trends in immunology
ISSN: 1471-4981
Titre abrégé: Trends Immunol
Pays: England
ID NLM: 100966032
Informations de publication
Date de publication:
01 2024
01 2024
Historique:
received:
24
10
2023
revised:
17
11
2023
accepted:
18
11
2023
pmc-release:
01
01
2025
medline:
15
1
2024
pubmed:
17
12
2023
entrez:
16
12
2023
Statut:
ppublish
Résumé
Current seasonal influenza vaccines, which mainly target hemagglutinin (HA), require annual updates due to the continuous antigenic drift of the influenza virus. Developing an influenza vaccine with increased breadth of protection will have significant public health benefits. The recent discovery of broadly protective antibodies to neuraminidase (NA) has provided important insights into developing a universal influenza vaccine, either by improving seasonal influenza vaccines or designing novel immunogens. However, further in-depth molecular characterizations of NA antibody responses are warranted to fully leverage broadly protective NA antibodies for influenza vaccine designs. Overall, we posit that focusing on NA for influenza vaccine development is synergistic with existing efforts targeting HA, and may represent a cost-effective approach to generating a broadly protective influenza vaccine.
Identifiants
pubmed: 38103991
pii: S1471-4906(23)00255-7
doi: 10.1016/j.it.2023.11.001
pmc: PMC10841738
mid: NIHMS1947174
pii:
doi:
Substances chimiques
Influenza Vaccines
0
Neuraminidase
EC 3.2.1.18
Antibodies, Viral
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-19Subventions
Organisme : NIAID NIH HHS
ID : R01 AI168178
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI150747
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI165475
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI141990
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI144616
Pays : United States
Organisme : NCCIH NIH HHS
ID : DP2 AT011966
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests N.C.W. is a consultant for HeliXon. The laboratory of A.H.E. received funding under sponsored research agreements from Moderna, Emergent BioSolutions, and AbbVie. A.H.E. has received consulting and speaking fees from InBios International, Inc., Fimbrion Therapeutics, RGAX, Mubadala Investment Company, Moderna, Pfizer, GSK, Danaher, Third Rock Ventures, Goldman Sachs, and Morgan Stanley and is the founder of ImmuneBio Consulting.
Références
J Virol. 2016 Apr 14;90(9):4720-4734
pubmed: 26912624
Curr Top Microbiol Immunol. 2015;386:181-204
pubmed: 25059893
Am J Hyg. 1945 Nov;42:307-22
pubmed: 21005133
J Infect Dis. 2018 Jul 2;218(3):347-354
pubmed: 29506129
Cold Spring Harb Perspect Med. 2020 Aug 3;10(8):
pubmed: 31871236
Science. 2021 Aug 27;373(6558):991-998
pubmed: 34214046
Immunity. 2023 Nov 14;56(11):2621-2634.e6
pubmed: 37967533
Vaccine. 2002 Feb 22;20(11-12):1670-4
pubmed: 11858877
J Exp Med. 1942 Jan 1;75(1):49-64
pubmed: 19871167
Vet Ital. 2019 Sep 30;55(3):195-201
pubmed: 31599544
Vaccine. 1998 May-Jun;16(9-10):1009-15
pubmed: 9682352
Annu Rev Virol. 2020 Sep 29;7(1):495-512
pubmed: 32392457
Immunity. 2020 Oct 13;53(4):852-863.e7
pubmed: 32976769
NPJ Vaccines. 2021 Dec 17;6(1):154
pubmed: 34921149
Nature. 1981 Jan 29;289(5796):366-73
pubmed: 7464906
Nat Med. 2021 Jan;27(1):106-114
pubmed: 33288923
Nat Commun. 2023 Oct 4;14(1):6195
pubmed: 37794071
Science. 2019 Oct 25;366(6464):499-504
pubmed: 31649200
Influenza Other Respir Viruses. 2012 Jul;6(4):245-56
pubmed: 22085243
ACS Cent Sci. 2022 Dec 28;8(12):1646-1663
pubmed: 36589893
PLoS One. 2008;3(12):e3942
pubmed: 19079604
Biochem J. 1961 Nov;81:384-92
pubmed: 13860975
Proc Natl Acad Sci U S A. 1990 Jan;87(2):786-90
pubmed: 2300562
Ther Adv Vaccines. 2015 Jul;3(4):97-108
pubmed: 26478817
Open Forum Infect Dis. 2015 Jan 03;2(1):ofu115
pubmed: 25884004
Nat Struct Mol Biol. 2018 Feb;25(2):115-121
pubmed: 29396418
Cell Host Microbe. 2019 Dec 11;26(6):729-738.e4
pubmed: 31757767
Nature. 2023 Jun;618(7965):590-597
pubmed: 37258672
Science. 2021 Feb 12;371(6530):735-741
pubmed: 33436524
J Gen Microbiol. 1963 Aug;32:225-33
pubmed: 14053269
Science. 2009 Apr 10;324(5924):246-51
pubmed: 19251591
mBio. 2023 Jun 27;14(3):e0008423
pubmed: 37070986
J Mol Biol. 2003 Dec 5;334(4):733-49
pubmed: 14636599
Vaccines (Basel). 2020 Jul 23;8(3):
pubmed: 32718039
J Infect Dis. 2015 Oct 15;212(8):1191-9
pubmed: 25858957
Mol Cell Biol. 1983 Dec;3(12):2156-65
pubmed: 6318086
Hum Vaccin Immunother. 2018;14(8):1874-1882
pubmed: 29672213
Nature. 1983 May 5-11;303(5912):41-4
pubmed: 6188957
Cell Host Microbe. 2019 Dec 11;26(6):715-728.e8
pubmed: 31757769
NPJ Vaccines. 2021 May 13;6(1):70
pubmed: 33986287
Sci Transl Med. 2023 Apr 19;15(692):eade4976
pubmed: 37075126
Nature. 1981 Jan 29;289(5796):373-8
pubmed: 6162101
Science. 1962 Oct 5;138(3536):42-3
pubmed: 13901412
J Virol. 2017 Nov 30;91(24):
pubmed: 28978710
Influenza Other Respir Viruses. 2008 Nov;2(6):211-9
pubmed: 19453397
Nat Struct Mol Biol. 2009 Mar;16(3):265-73
pubmed: 19234466
mBio. 2018 Apr 3;9(2):
pubmed: 29615508
Immunity. 2023 Aug 8;56(8):1927-1938.e8
pubmed: 37506693
Nat Commun. 2022 Apr 5;13(1):1825
pubmed: 35383176
Curr Opin Immunol. 2018 Aug;53:96-101
pubmed: 29730560
Viruses. 2019 Apr 16;11(4):
pubmed: 31014029
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
J Clin Invest. 2018 Nov 1;128(11):4992-4996
pubmed: 30188868
Cell Rep. 2023 Jan 31;42(1):111951
pubmed: 36640354
J Infect Dis. 1974 Apr;129(4):411-20
pubmed: 4593871
Elife. 2020 Aug 04;9:
pubmed: 32748788
J Infect Dis. 2013 Mar 15;207(6):974-81
pubmed: 23307936
J Clin Invest. 2019 Feb 1;129(2):850-862
pubmed: 30521496
Nat Immunol. 2019 Mar;20(3):362-372
pubmed: 30742080
Cell Host Microbe. 2019 Jun 12;25(6):827-835.e6
pubmed: 31104946
Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):5986-91
pubmed: 18413603
Nature. 1983 May 5-11;303(5912):35-40
pubmed: 6843658
J Virol. 2013 Aug;87(16):9290-300
pubmed: 23785204
Curr Opin Immunol. 2018 Aug;53:38-44
pubmed: 29674167
Cell. 2018 Apr 5;173(2):417-429.e10
pubmed: 29625056
Clin Diagn Lab Immunol. 1996 Sep;3(5):511-6
pubmed: 8877127
Nat Med. 2015 Sep;21(9):1065-70
pubmed: 26301691
Front Microbiol. 2021 Oct 04;12:729914
pubmed: 34671330
Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12578-12583
pubmed: 29109276
J Mol Biol. 1992 Sep 5;227(1):122-48
pubmed: 1381757
Lancet. 1973 Mar 24;1(7804):623-5
pubmed: 4121842
J Virol. 1993 May;67(5):2552-8
pubmed: 7682624
Vaccine. 2012 Dec 17;31(1):190-5
pubmed: 23107591
mBio. 2016 Apr 19;7(2):e00417-16
pubmed: 27094330
Nature. 2021 Apr;592(7855):623-628
pubmed: 33762730
J Virol. 2012 May;86(10):5774-81
pubmed: 22398287
ACS Infect Dis. 2018 May 11;4(5):788-796
pubmed: 29451984
Clin Infect Dis. 2020 Dec 15;71(12):3096-3102
pubmed: 31840159
mBio. 2020 Oct 6;11(5):
pubmed: 33024040
PLoS Pathog. 2017 Oct 23;13(10):e1006682
pubmed: 29059230
Vaccine. 2017 Sep 12;35(38):5209-5216
pubmed: 28789850
Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20748-53
pubmed: 22143798
Science. 2015 Sep 18;349(6254):1301-6
pubmed: 26303961
Vaccine. 2020 Oct 21;38(45):7129-7137
pubmed: 32943267
mBio. 2015 Mar 10;6(2):e02556
pubmed: 25759506
J Virol. 2014 Nov;88(22):13260-8
pubmed: 25210189
BMC Med. 2013 Jun 25;11:153
pubmed: 23800265
Influenza Other Respir Viruses. 2016 Sep;10(5):354-60
pubmed: 27426005
J Virol. 2014 Jan;88(1):699-704
pubmed: 24155380
Virology. 2012 Oct 10;432(1):39-44
pubmed: 22727831
Front Microbiol. 2019 Jan 29;10:39
pubmed: 30761095